aTyr Pharma ATYR Noncontrolling interests in subsidiaries
Noncontrolling interests in subsidiaries at other companies
Other financials
Where this comes from
Reported directly by aTyr Pharma in its filing.
Tagged under the XBRL concept us-gaap:MinorityInterest.
The official record: aTyr Pharma’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about aTyr Pharma's noncontrolling interests in subsidiaries.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is aTyr Pharma's noncontrolling interests in subsidiaries?
- aTyr Pharma (ATYR) reported noncontrolling interests in subsidiaries of -$193K in Q1 2026.
- How has aTyr Pharma's noncontrolling interests in subsidiaries changed year-over-year?
- aTyr Pharma's noncontrolling interests in subsidiaries decreased by 2.7% year-over-year, from -$188K to -$193K.
- What is the long-term trend for aTyr Pharma's noncontrolling interests in subsidiaries?
- Over 5 years (2020 to 2025), aTyr Pharma's noncontrolling interests in subsidiaries has grown at a 3.0% compound annual growth rate (CAGR), from -$166K to -$192K.
- What does noncontrolling interests in subsidiaries mean?
- This represents the portion of a subsidiary's net assets that is owned by outside shareholders rather than the parent company. It is reported within equity to show the total value of the subsidiary's assets and liabilities that are not attributable to the parent. It reflects the non-controlling stake in consolidated entities.